StreetInsider.com News Articles

Form S-8 CEL SCI CORP

Thu, 03 Sep 2026 16:47:00 -0400

si-local-file:///var/storage/secattach/20260903/27025741.html

Form 4 CEL SCI CORP For: Aug 25 Filed by: KERSTEN GEERT R

Wed, 26 Aug 2026 08:33:00 -0400

si-local-file:///var/storage/secattach/20260826/26977795.html

Form 4 CEL SCI CORP For: Aug 25 Filed by: KERSTEN GEERT R

Wed, 26 Aug 2026 08:33:00 -0400

si-local-file:///var/storage/secattach/20260826/26977795.html

Form 4 CEL SCI CORP For: Aug 14 Filed by: Watson Robert Eugene

Mon, 17 Aug 2026 09:43:00 -0400

si-local-file:///var/storage/secattach/20260817/26935988.html

Form 4 CEL SCI CORP For: Aug 14 Filed by: Watson Robert Eugene

Mon, 17 Aug 2026 09:43:00 -0400

si-local-file:///var/storage/secattach/20260817/26935988.html

Form 4 CEL SCI CORP For: Aug 14 Filed by: BAILLAVOINE BRUNO JEAN-MARIE

Mon, 17 Aug 2026 09:37:00 -0400

si-local-file:///var/storage/secattach/20260817/26935960.html

Form 4 CEL SCI CORP For: Aug 14 Filed by: BAILLAVOINE BRUNO JEAN-MARIE

Mon, 17 Aug 2026 09:37:00 -0400

si-local-file:///var/storage/secattach/20260817/26935960.html

Form 4 CEL SCI CORP For: Aug 14 Filed by: CIPRIANO JOHN

Mon, 17 Aug 2026 09:33:00 -0400

si-local-file:///var/storage/secattach/20260817/26935942.html

Form 4 CEL SCI CORP For: Aug 14 Filed by: CIPRIANO JOHN

Mon, 17 Aug 2026 09:33:00 -0400

si-local-file:///var/storage/secattach/20260817/26935942.html

Form 4 CEL SCI CORP For: Aug 14 Filed by: TALOR EYAL

Mon, 17 Aug 2026 09:27:00 -0400

si-local-file:///var/storage/secattach/20260817/26935901.html

Form 4 CEL SCI CORP For: Aug 14 Filed by: TALOR EYAL

Mon, 17 Aug 2026 09:27:00 -0400

si-local-file:///var/storage/secattach/20260817/26935901.html

Form 4 CEL SCI CORP For: Aug 14 Filed by: PRICHEP PATRICIA B

Mon, 17 Aug 2026 09:23:00 -0400

si-local-file:///var/storage/secattach/20260817/26935884.html

Form 4 CEL SCI CORP For: Aug 14 Filed by: PRICHEP PATRICIA B

Mon, 17 Aug 2026 09:23:00 -0400

si-local-file:///var/storage/secattach/20260817/26935884.html

Form 4 CEL SCI CORP For: Aug 14 Filed by: KERSTEN GEERT R

Mon, 17 Aug 2026 09:19:00 -0400

si-local-file:///var/storage/secattach/20260817/26935865.html

Form 4 CEL SCI CORP For: Aug 14 Filed by: KERSTEN GEERT R

Mon, 17 Aug 2026 09:19:00 -0400

si-local-file:///var/storage/secattach/20260817/26935865.html

Form 8-K CEL SCI CORP For: Aug 14

Mon, 17 Aug 2026 09:05:00 -0400

si-local-file:///var/storage/secattach/20260817/26935774.html

Form 8-K CEL SCI CORP For: Aug 14

Mon, 17 Aug 2026 09:05:00 -0400

si-local-file:///var/storage/secattach/20260817/26935774.html

CEL-SCI Reports Fiscal Third Quarter 2026 Results

Mon, 17 Aug 2026 08:30:00 -0400

Peer-reviewed study in Oral Oncology identified prognostic biomarkers for selecting patients most likely to achieve substantial survival benefit from Multikine in upcoming Confirmatory Head & Neck Cancer Registration Study
Dual track commercialization strategy includes the global Confirmatory Registration study to commence enrollment in the U.S., Europe, Asia and South America for U.S. FDA approval, with a parallel process in Saudi Arabia for Breakthrough Designation which could make Multikine commercially available in the near term
Signed key partnership with Amarox to advance Multikine approval and commercialization in Saudi Arabia

VIENNA, Va.--(BUSINESS WIRE)-- CEL-SCI Corporation (NYSE American:

CEL-SCI Reports Fiscal Third Quarter 2026 Results

Mon, 17 Aug 2026 08:30:00 -0400

Peer-reviewed study in Oral Oncology identified prognostic biomarkers for selecting patients most likely to achieve substantial survival benefit from Multikine in upcoming Confirmatory Head & Neck Cancer Registration Study

Dual track commercialization strategy includes the global Confirmatory Registration study to commence enrollment in the U.S., Europe, Asia and South America for U.S. FDA approval, with a parallel process in Saudi Arabia for Breakthrough Designation which could make Multikine commercially available in the near term

Signed key partnership with Amarox to advance Multikine approval and commercialization in Saudi Arabia

VIENNA, Va.--(BUSINESS WIRE)-- CEL-SCI Corporation (NYSE American:

CEL-SCI Reports Fiscal Third Quarter 2026 Results

Mon, 17 Aug 2026 08:30:00 -0400

Peer-reviewed study in Oral Oncology identified prognostic biomarkers for selecting patients most likely to achieve substantial survival benefit from Multikine in upcoming Confirmatory Head & Neck Cancer Registration Study

Dual track commercialization strategy includes the global Confirmatory Registration study to commence enrollment in the U.S., Europe, Asia and South America for U.S. FDA approval, with a parallel process in Saudi Arabia for Breakthrough Designation which could make Multikine commercially available in the near term

Signed key partnership with Amarox to advance Multikine approval and commercialization in Saudi Arabia

VIENNA, Va.--(BUSINESS WIRE)-- CEL-SCI Corporation (NYSE American:

CEL-SCI Reports Fiscal Third Quarter 2026 Results

Mon, 17 Aug 2026 08:30:00 -0400

Peer-reviewed study in Oral Oncology identified prognostic biomarkers for selecting patients most likely to achieve substantial survival benefit from Multikine in upcoming Confirmatory Head & Neck Cancer Registration Study

Dual track commercialization strategy includes the global Confirmatory Registration study to commence enrollment in the U.S., Europe, Asia and South America for U.S. FDA approval, with a parallel process in Saudi Arabia for Breakthrough Designation which could make Multikine commercially available in the near term

Signed key partnership with Amarox to advance Multikine approval and commercialization in Saudi Arabia

VIENNA, Va.--(BUSINESS WIRE)-- CEL-SCI Corporation (NYSE American:

CEL-SCI Reports Fiscal Third Quarter 2026 Results

Mon, 17 Aug 2026 08:30:00 -0400

Peer-reviewed study in Oral Oncology identified prognostic biomarkers for selecting patients most likely to achieve substantial survival benefit from Multikine in upcoming Confirmatory Head & Neck Cancer Registration Study

Dual track commercialization strategy includes the global Confirmatory Registration study to commence enrollment in the U.S., Europe, Asia and South America for U.S. FDA approval, with a parallel process in Saudi Arabia for Breakthrough Designation which could make Multikine commercially available in the near term

Signed key partnership with Amarox to advance Multikine approval and commercialization in Saudi Arabia

VIENNA, Va.--(BUSINESS WIRE)-- CEL-SCI Corporation (NYSE American:

CEL-SCI Reports Fiscal Third Quarter 2026 Results

Mon, 17 Aug 2026 08:30:00 -0400

Peer-reviewed study in Oral Oncology identified prognostic biomarkers for selecting patients most likely to achieve substantial survival benefit from Multikine in upcoming Confirmatory Head & Neck Cancer Registration Study

Dual track commercialization strategy includes the global Confirmatory Registration study to commence enrollment in the U.S., Europe, Asia and South America for U.S. FDA approval, with a parallel process in Saudi Arabia for Breakthrough Designation which could make Multikine commercially available in the near term

Signed key partnership with Amarox to advance Multikine approval and commercialization in Saudi Arabia

VIENNA, Va.--(BUSINESS WIRE)-- CEL-SCI Corporation (NYSE American:

CEL-SCI Reports Fiscal Third Quarter 2026 Results

Mon, 17 Aug 2026 08:30:00 -0400

Peer-reviewed study in Oral Oncology identified prognostic biomarkers for selecting patients most likely to achieve substantial survival benefit from Multikine in upcoming Confirmatory Head & Neck Cancer Registration Study

Dual track commercialization strategy includes the global Confirmatory Registration study to commence enrollment in the U.S., Europe, Asia and South America for U.S. FDA approval, with a parallel process in Saudi Arabia for Breakthrough Designation which could make Multikine commercially available in the near term

Signed key partnership with Amarox to advance Multikine approval and commercialization in Saudi Arabia

VIENNA, Va.--(BUSINESS WIRE)-- CEL-SCI Corporation (NYSE American:

CEL-SCI Reports Fiscal Third Quarter 2026 Results

Mon, 17 Aug 2026 08:30:00 -0400

Peer-reviewed study in Oral Oncology identified prognostic biomarkers for selecting patients most likely to achieve substantial survival benefit from Multikine in upcoming Confirmatory Head & Neck Cancer Registration Study

Dual track commercialization strategy includes the global Confirmatory Registration study to commence enrollment in the U.S., Europe, Asia and South America for U.S. FDA approval, with a parallel process in Saudi Arabia for Breakthrough Designation which could make Multikine commercially available in the near term

Signed key partnership with Amarox to advance Multikine approval and commercialization in Saudi Arabia

VIENNA, Va.--(BUSINESS WIRE)-- CEL-SCI Corporation (NYSE American: